Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07718724 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 Agonist

Study acronym: PRECISION
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Primary endpoints: details revised at 1 of 2 entries · Trial sites expanded: 1 → 20 locations · Start date changed from estimate of Aug 15, 2026 to Sep 5, 2026 · 3 more Show 6 more changesShow less
    • Primary endpoints: details revised at 1 of 2 entries
    • Trial sites expanded: 1 → 20 locations
    • Start date changed from estimate of Aug 15, 2026 to Sep 5, 2026
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 5 of 37 entries
    • Study description expanded, about 2 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Asthma
927 trials monitored
See 32 trials at risk
The primary objective of this study is to evaluate whether GDMT can bring significant benefits to disease management in uncontrolled asthma patients receiving medium- to high-dose ICS-LABA. * The intervention period will be up to 48 weeks; * The frequency of follow-up is every 12 weeks.
Trial Details
NCT Number NCT07718724
Lead Sponsor AstraZeneca
Conditions Uncontrolled Asthma
Enrollment 540 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov